atezolizumab,talazoparib
roche,pfizer
['atezo', 'talazo', 'biomarker', 'sclc']
es-sclc with expression of slfn11 (present in 50-70% of patients) given ep-atezo x4 wo progression given atezo + talazoparib maintenance improves pfs - 4.2 vs 2.8mo!! os data immature, but numerical improvement of 9.4 v 8.5mo).
a biomarker and improved pfs in 1l sclc!! #asco23 
Medical Oncologist. Chief of Hem/Onc, PD of hem/onc fellowship, Dr Peter White Endowed Professor, & Associate Professor at The University of Toledo.